News | Health & Safety
24 May 2017 12:27
NZCity News
NZCity CalculatorReturn to NZCity

  • Start Page
  • Personalise
  • Sport
  • Weather
  • Olympic Games
  • Finance
  • Shopping
  • Jobs
  • Horoscopes
  • Lotto Results
  • Photo Gallery
  • Site Gallery
  • TVNow
  • Dating
  • SearchNZ
  • NZSearch
  • Crime.co.nz
  • RugbyLeague
  • Make Home
  • About NZCity
  • Contact NZCity
  • Your Privacy
  • Advertising
  • Login
  • Join for Free

  •   Home > News > Health & Safety

    Pacific Edge gets $3m extension to grant

    Pacific Edge has won a two-year extension to its research grant to fund the development of its Cxbladder products for bladder cancer detection.


    Pacific Edge has won a two-year extension to its Callaghan Innovation research grant to fund the development of its Cxbladder diagnostic suite of products for bladder cancer detection.

    The Dunedin-based firm has received up to $3 million of extra funding for research and development spread over two years, on top of an initial three-year grant of $4.5m it received in 2014, it said in a statement.

    Since the first grant was awarded, Pacific Edge has launched three new products to add to the original bladder cancer diagnostics test, with each test addressing different clinical needs.

    The shares rose 3.5 per cent to 59 cents.

    "Investment into research and development is a major focus for Pacific Edge and we are continually looking at how we can provide better and more targeted diagnostic tools for clinicians and their patients," chief executive David Darling said.

    "The Growth Grant supplements Pacific Edge's own investment into R&D and will enable us to bring new innovations through into new products and product improvements."

    The company raised $8 million in February through a share placement to institutional investors to shore up its balance sheet as it ramps up efforts to lift commercial growth.

    It started making commercial sales in 2013 and at the time was targeting $100m in gross revenue within five years.

    The recent capital raise left it with $9m of cash to fund its immediate growth needs, and when reporting its first half result in November it signalled plans to have all four Cxbladder products fully launched in the US by 2018.

    # (BusinessDesk receives funding from Callaghan Innovation to help cover the commercialisation of innovation.)


    NZN




    © 2017 NZN, NZCity


     Other Health & Safety News
     24 May: AFT Pharma confident despite losses
     24 May: World record bungy attempt underway
     23 May: Macquarie lifts F&P price target 7.3pc
     23 May: Ebos to buy Australia's HPS for $165m
     22 May: F&P Healthcare profit up 18 per cent
     20 May: Syrian war: Wounded risking retribution to receive medical care from enemy Israel
     19 May: Ryman chalks up another record profit
     Top Stories

    RUGBY RUGBY
    Read happy to sign on with NZ Rugby again More...


    BUSINESS BUSINESS
    AFT Pharma confident despite losses More...



     Today's News

    Entertainment:
    Sharon Osbourne thinks she needs "therapy" for her television addiction 12:07

    Law and Order:
    Newshub car recovered; gear still missing 11:57

    Rugby:
    Read happy to sign on with NZ Rugby again 11:47

    Entertainment:
    Sadie Frost is open to the idea of getting married again 11:37

    Entertainment:
    Kelly Rohrbach is reportedly dating Steuart Walton 11:07

    Business:
    AFT Pharma confident despite losses 11:07

    Business:
    Fonterra lifts payout forecast 10:47

    Entertainment:
    Lena Dunham has axed her Lenny IRL tour due to complications with her endometriosis 10:37

    Business:
    Insurer Tower's losses narrow 10:27

    Entertainment:
    Dwayne 'The Rock' Johnson is flattered that people want him to be the next US president 10:07


     News Search






    Power Search


    © 2017 New Zealand City Ltd